Correction: Systematic preclinical evaluation of CD33-directed chimeric antigen receptor T cell immunotherapy for acute myeloid leukemia defines optimized construct design

Correction: Systematic preclinical evaluation of CD33-directed chimeric antigen receptor T cell immunotherapy for acute myeloid leukemia defines optimized construct design

Saved in:

Bibliographic Details
Format:	Article
Language:	English
Published:	BMJ Publishing Group 2021-10-01
Series:	Journal for ImmunoTherapy of Cancer
Online Access:	https://jitc.bmj.com/content/9/10/e003149corr1.full
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

In Vitro and In Vivo Antitumor Effect of Anti-CD33 Chimeric Receptor-Expressing EBV-CTL against CD33+ Acute Myeloid Leukemia
by: A. Dutour, et al.
Published: (2012-01-01)

Performance of anti-CD19 chimeric antigen receptor T cells in genetically defined classes of chronic lymphocytic leukemia
by: Veronika Mancikova, et al.
Published: (2020-05-01)

Recent advances of chimeric antigen receptor T‐cell therapy for acute myeloid leukemia
by: Yang Liu, et al.
Published: (2025-05-01)

CD22-targeted chimeric antigen receptor-modified T cells for children and adults with relapse of B-cell acute lymphoblastic leukemia after CD19-directed immunotherapy
by: Clare Taylor, et al.
Published: (2025-04-01)

Advancing Chimeric Antigen Receptor T-Cell Therapy for Acute Myeloid Leukemia: Current Limitations and Emerging Strategies
by: Daniela Damiani, et al.
Published: (2024-12-01)

A preclinical study of allogeneic CD19 chimeric antigen receptor double‐negative T cells as an off‐the‐shelf immunotherapy drug against B‐cell malignancies
by: Dan Wang, et al.
Published: (2024-01-01)

Discovery and preclinical development of a therapeutically active nanobody-based chimeric antigen receptor targeting human CD22
by: Scott McComb, et al.
Published: (2024-03-01)

MODERN IMMUNOTHERAPY OF ADULT B-LINEAGE ACUTE LYMPHOBLASTIC LEUKEMIA WITH MONOCLONAL ANTIBODIES AND CHIMERIC ANTIGEN RECEPTOR MODIFIED T CELLS
by: Elena Maino, et al.
Published: (2015-01-01)

In vivo programmed myeloid cells expressing novel chimeric antigen receptors show potent anti-tumor activity in preclinical solid tumor models
by: Shannon Argueta, et al.
Published: (2024-12-01)

Deletion of CD38 enhances CD19 chimeric antigen receptor T cell function
by: Kimberly Veliz, et al.
Published: (2024-06-01)

Recent Advance in Antigen-Specific Immunotherapy for Acute Myeloid Leukemia
by: Norimitsu Kadowaki, et al.
Published: (2011-01-01)

Current challenges and emerging opportunities of chimeric antigen receptor-engineered cell immunotherapy
by: Yong Liu, et al.
Published: (2025-07-01)

Research progress on chimeric antigen receptor-based immunotherapy against autoimmune diseases
by: Mingwei Jiang, et al.
Published: (2025-12-01)

Adoptitive immunotherapy with genetically engineered T lymphocytes modified to express chimeric antigen receptors
by: A. А. Pavlova, et al.
Published: (2017-04-01)

Prospects for γδ T cells and chimeric antigen receptor γδ T cells in cancer immunotherapy
by: Lu Wang, et al.
Published: (2025-04-01)

Defining ‘Intention’ in intention-to-treat survival outcomes for chimeric antigen receptor T-cell therapy
by: Charles J. Milrod, et al.
Published: (2025-02-01)

Capivasertib enhances chimeric antigen receptor T cell activity in preclinical models of B cell lymphoma
by: Hui-Ju Hsieh, et al.
Published: (2025-03-01)

Invasive Fungal Disease After Chimeric Antigen Receptor-T Immunotherapy in Adult and Pediatric Patients
by: Paschalis Evangelidis, et al.
Published: (2025-02-01)

Clonal evolution and the risk of secondary myeloid neoplasia following chimeric antigen receptor T-cell therapy
by: Francesca Sillito, et al.
Published: (2025-04-01)

Decentralized Point-of-Care Manufacturing of CD19 Chimeric Antigen Receptor T Cells in Mexico
by: Rosario Salazar-Riojas, et al.
Published: (2025-04-01)

Research progress on HER2-specific chimeric antigen receptor T cells for immunotherapy of solid tumors
by: Liaoliao Zhu, et al.
Published: (2025-05-01)

MUC18-Directed chimeric antigen receptor T cells for the treatment of mucosal melanoma
by: Fenghao Zhang, et al.
Published: (2025-04-01)

Cytomorphology of Chimeric Antigen Receptor T-Cells (CAR-T)
by: Eugenio Galli, et al.
Published: (2021-10-01)

GENERATION OF CD34+ DERIVED HUMAN MACROPHAGE EXPRESSING CHIMERIC ANTIGEN RECEPTORS FOR CANCER TREATMENT
by: Ian-Costa, et al.
Published: (2024-10-01)

Efficacy and safety of CD19 combined with CD22 or CD20 chimeric antigen receptor T-cell therapy for hematological malignancies
by: Xiaoshuang Yuan, et al.
Published: (2025-05-01)

Immunosuppressive role of CD11b+CD33+HLA‐DR− myeloid‐derived suppressor cells‐like blast subpopulation in acute myeloid leukemia
by: Shin Young Hyun, et al.
Published: (2020-10-01)

Chimeric antigen receptor dendritic cells targeted delivery of a single tumoricidal factor for cancer immunotherapy
by: Rong Duan, et al.
Published: (2024-08-01)

The Struggle Between Chimeric Antigen Receptor T-Cell Therapy and Neurological Complications in Acute Lymphoblastic Leukemia Treatment
by: Norwin Kubick, et al.
Published: (2025-05-01)

Evaluation of Intracellular Signaling Downstream Chimeric Antigen Receptors.
by: Hannah Karlsson, et al.
Published: (2015-01-01)

Advance in chimeric antigen receptor T therapy in autoimmune diseases
by: Xiaolan Ji, et al.
Published: (2025-03-01)

Case Report: Bispecific CD20/CD30-targeted chimeric antigen receptor T-cell therapy for non-Hodgkin’s lymphoma
by: Yuejiao Huang, et al.
Published: (2025-05-01)

Impact of immunosuppressant in children with B-cell Acute Lymphoblastic Leukemia following Chimeric Antigen Receptor T-cell Therapy
by: Hui Zhang, et al.
Published: (2025-06-01)

CD47 antibody-armed oncolytic adenovirus promotes chimeric antigen receptor macrophage phagocytosis and antitumor immunity
by: Zhongbing Qi, et al.
Published: (2025-08-01)

First pediatric B-acute lymphoblastic leukemia patient treated with anti-CD19 chimeric antigen receptor T-cell therapy: Long-term remission or early cure?
by: Dimitrios Bouzianas, et al.
Published: (2024-12-01)

The efficacy of chimeric antigen receptor (CAR) immunotherapy in animal models for solid tumors: A systematic review and meta-analysis.
by: Yingcheng Wu, et al.
Published: (2017-01-01)

Chimeric antigen receptor-natural killer (CAR-NK) cell immunotherapy: A bibliometric analysis from 2004 to 2023
by: Wangshu Li, et al.
Published: (2024-12-01)

Extracellular domain, hinge, and transmembrane determinants affecting surface CD4 expression of a novel anti-HIV chimeric antigen receptor (CAR) construct.
by: Giorgio Zenere, et al.
Published: (2024-01-01)

The potential of chimeric antigen receptor -T cell therapy for endocrine cancer
by: Ruonan Yu, et al.
Published: (2025-04-01)

Cardiovascular toxicities associated with chimeric antigen receptor T-cell therapy
by: Jia-Hui Liu, et al.
Published: (2025-05-01)

Allogeneic CD33-directed CAR-NKT cells for the treatment of bone marrow-resident myeloid malignancies
by: Yan-Ruide Li, et al.
Published: (2025-02-01)